Caicun Zhou
Tracked across 2 events · 20 articles · First seen May 30, 2026 · Last active Sep 13, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Akeso announced that a pre-specified interim analysis of overall survival (OS) in the Phase III HARMONi-2 (AK112-303) trial, assessed by the Independent Data Monitoring Committee, met the key secondary OS endpoint. Ivonescimab, Akeso's first-in-class PD-1/VEGF…
Impact: Caicun Zhou is the HARMONi-2 principal investigator and IASLC President who will deliver the formal oral presentation of the complete OS results on September 15, 2026.
Jul 20, 2026 · 6 articles
Tech
Impact: Professor Caicun Zhou presented the positive results of the OptiTROP-Lung05 study, highlighting its potential to bring new treatment options for lung cancer patients.
May 30, 2026 · 14 articles
25
Caicun Zhou delivered oral presentationIvonescimab HARMONi-2...
ERGEN INTELLIGENCE
Track Caicun Zhou live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard